Takeda, Azurity Unit Settle Patent Suit on Lupin’s Edarbi Copies

Takeda Pharmaceutical Co. and Arbor Pharmaceuticals LLC settled a lawsuit over Lupin Ltd.’s proposed generic version of Edarbi, which they had alleged infringes three patents Takeda licenses to Arbor for the drug, used to treat high blood pressure.

No details were provided in the stipulation and order of dismissal without prejudice, approved Monday by Judge Maryellen Noreika in the U.S. District Court for the District of Delaware.

Edarbi is an angiotensin II receptor blocker that prevents the narrowing of blood vessels, reducing blood pressure and improving blood flow.

Arbor and Takeda sued Lupin in July 2020. A 5-day bench trial ...